ProCE Banner Activity


Treatment of Progressing Desmoid Tumors: Future Directions

Text Module

Read this text module to learn about emerging therapies for the treatment of progressing desmoid tumors.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 15, 2023

Expiration: March 14, 2024

No longer available for credit.



Bernd Kasper

Bernd Kasper, MD, PhD

Associate Professor
University of Heidelberg
Mannheim University Medical Center
Mannheim Cancer Center, Sarcoma Unit
Mannheim, Germany

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported by an educational grant from

SpringWorks Therapeutics Inc

Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who care for patients with desmoid tumors.

Program Learning Goal

The goal of this program is to improve the knowledge, confidence, and competence of learners in understanding the latest science, emerging conference and clinical trial data, and ongoing clinical trials in precision therapies in desmoid tumors.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appraise the role of precision systemic therapies in DT management

  • Evaluate the emerging clinical trial evidence investigating the use of gamma secretase inhibitors in progressing DTs

  • Plan treatment for patients with progressive, unresectable, recurrent, or refractory DTs based on available clinical data, new and evolving approvals, and expert recommendations


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Bernd Kasper, MD, PhD: consultant/advisor/speaker: Ayala, Bayer, Boehringer Ingelheim, GlaxoSmithKline, PharmaMar, SpringWorks; researcher: PharmaMar, Rain Therapeutics, SpringWorks.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from start date, through expiration date:

  1. Create an account or Login at
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education

Credit Designation
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.